HALT

HALT investigates a treatment option for advanced non-small cell lung cancer.

Disease site: Lung cancer

Treatment Modality:

Status: In follow-up

What is the study about? 

HALT investigates a treatment option for advanced non-small cell lung cancer. 

Non-small cell lung cancer is the most common type of lung cancer, affecting around 9 in 10 of people diagnosed. Some people with this type of cancer have certain genetic abnormalities, or mutations, in their cancer cells which can be treated with drugs called tyrosine kinase inhibitors (TKI). 

Tyrosine kinase inhibitors often work well to start with but then stop working as well because cancer cells build a resistance to them. This can lead to areas of cancer growing, or progressing, around the body. The HALT trial is looking at whether treating small areas of progression with a type of very precisely targeted radiotherapy called stereotactic body radiotherapy (SBRT) can help the tyrosine kinase inhibitor work better for longer.

The results of the HALT trial will be used to help decide if SBRT would be a helpful treatment for small areas of progression in people with this type of cancer in future.

 

Who is included in the study? 

HALT includes people with advanced non-small cell lung cancer (NSCLC) which has spread around their body. Everyone who joins HALT will already be receiving tyrosine kinase inhibitor (TKI) treatment and will have developed five or fewer small areas of cancer growth during TKI treatment. 

110 participants will join HALT from NHS hospitals and from European hospitals in the European Organisation for Research and Treatment of Cancer.

 

What are the study treatments? 

Participants will be in two treatment groups:
• Continuing to take a tyrosine kinase inhibitor
• Continuing to take a tyrosine kinase inhibitor plus as short course of stereotactic body radiotherapy 

Participants will have regular check ups during and after their treatment and we will collect information about how they are getting on until the study is completed.

Further information for participants 

Patient information sheet

A detailed summary in plain English is also available on Cancer Research UK's website. 

Further information for health care professionals 

Protocol

Trial schema

breast cancer cell
Major trial shows prolonged benefit of olaparib in early-stage inherited breast cancer

12/12/24

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.
See full story
Breast cancer cell spheroid blue and purple
New understanding of aggressive form of breast cancer paves the way for tests and treatments

10/12/24

Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.
See full story